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Table 1. Sample Characteristics and Symptom Burden Means
cGVHD
(N5 116)
No cGVHD
(N5 58)
Mean (SD) Mean (SD) P
Age in yrs 49.7 (12.33) 50.6 (15.32) 0.700
Oral Presentations S177especially those with older age, chronic GVHD and recipients of
peripheral blood grafts. The incidence for solid cancers continues
to increase with time and life-long cancer surveillance is warranted
in this population.
Risk factors for solid cancers
Risk factor RR (95%CI) Education in yrs 14.7 (1.85) 14.4 (1.97) 0.340
All symptom items 2.65 (1.69) 1.67 (1.46) \0.0001*Age (years)
Core symptom items 2.34 (1.73) 1.77 (1.62) 0.040*\20 1.0
cGVHD symptom items 3.46 (2.08) 1.39 (1.44) \0.0001*20-40 2.4 (0.7-8.1)
Muscle weakness 3.92 (2.74) 1.57 (1.98) \0.0001*.40 6.2 (1.9-20.4)**
Changes in sexual function 3.70 (3.69) 1.57 (2.70) \0.0001*Chronic GVHD
Skin problems 3.37 (2.99) 0.83 (1.58) \0.0001*No 1.0
Eye problems 3.31 (3.09) 1.22 (2.52) \0.0001*Yes 2.6 (1.5-4.6)**
Joint stiffness of soreness 3.06 (3.20) 1.74 (@.32) 0.006*Graft type
Interference items 3.05 (2.37) 2.38 (2.38) 0.080Bone marrow 1.0Peripheral blood 2.5 (1.3-4.5)**
Number (%) Number (%)GVHD prophylaxisGender 0.023*T-cell depletion (ex-vivo) 1.0
Male 73 (62.9) 26 (44.8)ATG/campath 0.5 (0.1-2.4)
Female 43 (37.1) 32 (55.2)MTX1CSA 0.3 (0.1-0.9)*
Race/Ethnicity 0.472
Black/Hispanic 21 (18.1) 8 (13.8)
White 95 (81.9) 50 (86.2)*P\0.05, **P\0.01.Employment Status 0.433
Employed 48 (41.4) 27 (46.6)
Unemployed 68 (58.6) 31 (53.4)
Marital Status 0.356
Married 82 (70.7) 37 (63.8)
Single 34 (29.3) 21 (36.2)
Performance Status 0.297
Good (0-1) 77 (66.4) 43 (74.1)
Poor (2-4) 39 (33.6) 15 (25.9)
Underlying Disease 0.652
Leukemia 72 (62.1) 38 (65.5)
Lymphoma 33 (28.4) 13 (22.4)
Other 11 (9.5) 7 (12.1)
Donor 0.024*
Related 71 (61.2) 25 (43.1)
Unrelated 45 (38.8) 33 (59.9)
Type of Cells 0.249
Peripheral Stem Cells 83 (71.6) 45 (77.6)
Bone Marrow 29 (25.0) 9 (15.5)
Cord Blood 4 (3.4) 4 (6.8)
Occurrence of Acute GVHD \0.0001*
Yes 77 (66.4) 13 (22.4)
No 39 (33.6) 45 (77.6)
*significant at \0.05 level N5number of subjects P5probability
SD5standard deviation.60
A NEW MEASURE OF SYMPTOM BURDEN IN CHRONIC GRAFT-VERSUS-
HOST DISEASE
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Significance: Chronic graft-versus-host disease (cGVHD) can
cause debilitating symptoms after allogeneic hematopoietic stem
cell transplantation (alloHSCT). A major barrier to effective
treatment of the symptom burden of cGVHD is inadequate as-
sessment.
Problem and Purpose:The symptom burden of cGVHDcannot be
effectively assessed for research and clinical management without
a psychometrically sound, easily administered measure. The purpose
of this research was to develop a valid, reliable, and sensitive measure
of cGVHD symptom burden, based on the M. D. Anderson Symp-
tom Inventory (core MDASI).
Methods: 116 patients with cGVHD and 58 patients without
cGVHD.3 months after alloHSCT completed the 13 symptom se-
verity and 6 interference items of the core MDASI and 14 additional
cGVHD-specific symptom items, generated from patient interviews
and expert panel ratings. Severity and interference were measured on
a 0-10 scale, with 0 meaning none and 10 meaning the worst imagin-
able. Patients with cGHVD answered a single quality-of-life ques-
tion and 3 days later repeated the symptom burden assessment.
Demographic and disease information was collected on all patients.
Psychometric techniques reduced the number of symptom items and
examined the reliability, validity, and sensitivity of the MDASI for
cGVHD (MDASI-GVH).
Results: Sample demographics, disease characteristics, and symp-
tom severity and interference are shown in Table 1. Five new
cGVHD-related items (see Table 1) were found to be clinically sig-
nificant and were retained in the MDASI-GVH. The reliability in-
dex (Cronbach alpha) and test-retest reliability of all 18 symptom
items were 0.90 and 0.82 respectively and of the 6 interference items
were 0.91 and 0.75 respectively. Factor analysis showed the
cGVHD-related symptom items to be a unique factor. The
MDASI-GVH was sensitive to the presence of cGHVD, was able
to discriminate between patients with good and poor performance
status, and was significantly correlated with patient report of overall
quality of life. Symptom severity explained 77.2% of the variance in
interference, with the core symptoms explaining 76.1% and the
cGVHD-related symptoms explaining 55.9%.Implications: We have validated a new analytic tool, the MDASI-
GVH, for quantifying symptom burden produced by cGVHD.
TheMDASI-GVH has the potential to be utilized for quantitatively
assessing response in cGVHD treatment trials and monitoring the
course of cGVHD in clinical care.LEUKEMIA
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EXTRAMEDULLARY RELAPSE IN ACUTE LEUKEMIA FOLLOWING ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: INCIDENCE,
RISK FACTORS AND OUTCOMES
Harris, A.C., Mageneau, J., Braun, T., Kitko, C.L., Choi, S.W.,
Ferrara, J.L.M., Mineishi, S., Pawarode, A., Peres, E., Reddy, P.,
Yanik, G., Levine, J.E. University of Michigan, Ann Arbor, MI
Extramedullary (EM) relapse after allogeneic hematopoietic cell
transplantation (HCT) for acute leukemia has not been extensively
studied. Therefore, we analyzed 365 consecutive patients (pts) who
Risk factors for EM relapse following allogeneic HCT for acute leukemia
Characteristics
Percent of pts
w/ AML EM
relapse (n5 26)
Percent of all other
AML pts (n5 231)
Hazard Ratio
(p-value)
Percent of patients
with ALL EM
relapse (n5 23)
Percent of all
other ALL patients
(n5 85)
Hazard Ratio
(p-value)
FAB M4/M5 50% (n5 13) 30% (n5 70) 2.5 (0.02)
Age\18 years at diagnosis 35% (n5 9) 13% (n5 31) 3.1 (0.006) 43% (n5 10) 38% (n5 32) 1.1 (0.71)
EM disease prior to HCT 35% (n5 9) 10% (n5 22) 4.6 (\0.001) 57% (n5 13) 35% (n5 30) 1.7 (0.23)
High risk cytogenetics1 54% (n5 14) 27% (n5 62) 2.9 (0.006) 26% (n5 6) 39% (n5 33) 0.6 (0.26)
Advanced disease at HCT2 62% (n5 16) 36% (n5 83) 2.6 (0.02) 43% (n5 10) 24% (n5 20) 2.7 (0.02)
TBI in conditioning 12% (n5 3) 10% (n5 23) 1.3 (0.70) 47% (n5 11) 71% (n5 65) 0.4 (0.02)
Myeloablatvie conditioning 96% (n5 25) 80% (n5 184) 5.8 (0.08) 91% (n5 21) 95% (n5 81) 0.4 (0.22)
HLA matched donor 96% (n5 25) 83% (n5 192) 2.7 (0.10) 91% (n5 21) 84% (n5 71) 4.8 (0.13)
1High risk cytogenetics defined as complex karyotype, 5q-, monosomy7/7q-, and/or FLT-3 positive for AML and MLL gene rearrangement and/or Phil-
adelphia chromosome in ALL.
2Advanced disease defined as CR31 or refractory disease at time of transplant.
S178 Oral Presentationsunderwent allogeneic HCT for acute leukemia at the University of
Michigan between January 2001 and May 2008 to characterize EM
relapse, identify predictive variables and assess outcomes.
Following HCT for AML in 257 pts, the 5-yr cumulative inci-
dences of isolated EM and marrow relapse were 9% (n5 24) and
29% (n5 73), respectively. Combined relapse occurred in \1%
of pts (n5 2). EM relapse occurred later than marrow relapse
(median 348d vs. 112d, p\0.001). Skin and soft tissue were
most frequently involved (69%, n5 18). Factors predictive of
EM relapse included advanced disease (CR3+/refractory) at HCT
(HR5 2.6, p5 0.02), high risk cytogenetics (HR5 2.9,
p5 0.006), and AML FAB class M4 or M5 (HR5 2.5, p5 0.02).
These factors also predicted future marrow relapse. A history of
EM disease prior to HCT was predictive of future EM relapse
(HR5 4.6, p\0.001), but not marrow relapse (HR5 1.2,
p5 0.63). Interestingly, pts aged #18 at diagnosis were more likely
to develop EM relapse than adults (HR5 3.1, p50.006). Treat-
ment for EM relapse included systemic chemotherapy (n5 19), ra-
diation to chloromas (n5 12), and/or DLI (n5 8). Overall survival
after EM relapse was 30% at 1-yr and 11% at 2-yrs.
In 108 pts receiving HCT for ALL, the 5-yr cumulative incidence
of isolated EM relapse was 15% (n5 16), isolated marrow relapse
was 19% (n5 19) and combined relapse was 6% (n5 7). Isolated/
combined EM relapses occurred later than isolated marrow relapse
(median 260d vs. 96d, p5 0.05). EM relapse most often occurred
in the classic ALL sanctuary sites, CNS and testes (61%, n5 14),
but chloromas also occurred. Seven of 12 pts with CNS relapse
had received craniospinal radiation pre-HCT. Factors related to
EM relapse included advanced disease at HCT (HR5 2.7,
p5 0.02) and TBI-based conditioning (HR 0.4, p5 0.02), a pattern
echoed in marrow relapse. Unlike in AML, EM disease prior to
HCT did not predict EM relapse (HR5 1.7, p5 0.23). Treatments
for EM relapse included systemic chemotherapy (n5 15), radiation
to EM sites (n5 8), and/or DLI (n5 1). Overall survival after EM
relapse was 34% at 1-yr and 20% at 2-yrs.
Isolated EM relapse after allogeneic HCT for acute leukemia is
a surprisingly significant contributor to relapse. As with marrow re-
lapses, current treatment strategies salvage only a small proportion
of pts.62
PROGNOSIS OF ADULT PATIENTS WITH NON-M3 AML AFTER FIRST RE-
LAPSE
Kurosawa, S.1, Yamaguchi, T.2, Uchida, N.3, Sakura, T.4,
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pan; 2University of Tokyo, Japan; 3Toranomon Hospital, Japan; 4Saisei-
kai Maebashi Hospital; 5Kanagawa Cancer Center, Japan; 6NTT Kanto
Medical Center, Japan; 7Tokyo Metropolitan Komagome Hospital, Japan;
8Fujita Health University, Japan; 9Kurume University, Japan; 10Jikei
University, Japan; 11Ehime Prefectural Central Hospital, Matsuyama,
Japan; 12Nagasaki University, Japan; 13Nihon University, JapanBackground:The prognosis of patients who suffered first relapse re-
mains challenging, with little available prognostic factors. To clarify
factors predicting outcome of these patients, we performed a nation-
wide retrospective survey of 1,015 relapsed patients.
Methods:We collected clinical data of 2,029 patients from 70 cen-
ters, who were diagnosed with AML other than M3 between 1999
and 2006, aged 16 to 70 years, andwho had achieved complete remis-
sion (CR1) after 1 or 2 courses of induction chemotherapy.
Results: Of the 1,535 patients who did not receive allo-HCT in
CR1, 1,015 relapsed and were eligible for this analysis. The median
age was 53 years, and the median follow-up of the surviving pa-
tients was 1,457 days. The proportions of patients with favorable,
intermediate, unfavorable and unknown cytogenetic risks by
SWOG criteria were, respectively, 21%, 52%, 17% and 10%.
The median interval from CR1 to relapse was 264 days. The
3-year overall survival (OS) after relapse was 30%. Of the 931 pa-
tients whose detailed clinical data following first relapse were avail-
able, 464 achieved CR2 (50%). The 3-year OS after relapse of the
patients who achieved CR2 and those who did not were 48% and
11%, respectively (p\0.001). Among the 931 patients who experi-
enced first relapse, 494 received salvage allo-HCT. Donor sources
for salvage HCT were HLA-matched related (29%), mismatched
related (10%), unrelated BM (37%), or unrelated CB (23%). The
conditioning regimens were myeloablative (65%, median age: 37
years) or reduced-intensity (35%, median age: 55 years) regimens.
The 3-year OS of 494 patients who received salvage allo-HCT was
44%, whereas that of the remaining 437 patients who did not was
12% (p\0.001). The OS of the 306 patients who received salvage
HCT in CR2 was comparable to that of patients who received allo-
HCT in CR1 (3-year OS after CR1, 67% vs. 67%). Multivariate
analyses showed that an interval from CR1 to relapse (.1 year),
performance of salvage allo-HCT, a single course of induction
therapy to achieve CR1, and favorable cytogenetic risk were signif-
icantly associated with better survival after relapse. In addition, lack
of dysplasia and lower WBC count (\20,000/ml) at diagnosis be-
sides the above prognostic factors for OS were significantly associ-
ated with achievement of CR2.
Conclusion: Our data suggest that patients who achieve CR2 after
relapse would have moderate prognosis especially when a salvage
allo-HCT is performed during CR2.63
PRE-TRANSPLANT CONSOLIDATION CHEMOTHERAPY DOES NOT IM-
PROVE RATES OF RELAPSE FOLLOWING REDUCED INTENSITY CONDI-
TIONING (RIC) HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT)
FOR AML IN CR1
McCormack, S.E.1, Cao, Q.2, Warlick, E.D.1 1University of Minnesota,
Minneapolis, MN; 2University of Minnesota, Minneapolis, MN
Background: RIC HCT is an evolving post-remission treatment
modality for AML. While previous reports demonstrate no benefit
to consolidation chemotherapy prior tomyeloablative HCT, the im-
pact on outcomes post RIC HCT is unknown.
Methods and Patients: We retrospectively reviewed all adult pa-
tients at the University of Minnesota undergoing a RIC HCT for
